Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM™ (aducanumab-avwa). The publication notes that the importance of the manuscript is, “The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-β (Aβ)-targeting monoclonal antibody, in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.”  

The combined studies consisted of a total of 3,285 participants with Alzheimer’s disease who received 1 or more doses of placebo (n=1087) or aducanumab (n=2198; 2752 total person-years of exposure) during the placebo-controlled period. 

The complete publication is available on the JAMA Neurology website.  

 

Type Press Release

Date Released November 22, 2021

RECENT RELEASES
Mar 23, 2023

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup...

Mar 22, 2023

Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai's Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer's Disease...

Mar 19, 2023

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ)...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields